市场调查报告书
商品编码
1378996
寡核苷酸合成市场:2023-2028 年全球产业趋势、份额、规模、成长、机会与预测Oligonucleotide Synthesis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年全球寡核苷酸合成市场规模达27亿美元。展望未来, IMARC Group预计到2028年市场规模将达到55亿美元,2022-2028年复合年增长率(CAGR)为12.6%。遗传疾病在大众中的日益流行、新型治疗策略的开发以及使用小干扰 RNA (siRNA) 和反义寡核苷酸的疗法的广泛采用是推动市场的一些主要因素。
寡核苷酸合成是指依照预定序列建构短 DNA 或 RNA 分子(称为寡核苷酸)的过程。它们的长度范围可以从几个碱基到大约 200 个核苷酸。该过程是在受控实验室环境中以化学方式完成的,通常使用固相亚磷酰胺化学。在这种方法中,核苷酸被顺序添加到不断增长的链中,每次添加都涉及一系列化学反应。该技术使科学家能够产生用于各种应用的客製化寡核苷酸,包括基因合成、聚合酶炼式反应 (PCR)、基因编辑工具(如 CRISPR-Cas9)和分子诊断测试。寡核苷酸合成的进步极大地加速了基因组学和分子生物学的研究,为医学和生物学研究的许多突破奠定了基础。
大众遗传疾病盛行率的上升主要推动了全球市场。这就需要开发新的治疗策略,其中基于寡核苷酸的疗法发挥重要作用。例如,正在研究使用小干扰 RNA (siRNA) 和反义寡核苷酸的疗法,并将其用于治疗遗传性疾病,例如杜氏肌肉营养不良症和脊髓性肌肉萎缩症。因此,遗传疾病的日益普及推动了全球范围内的需求。同时,生物资讯学和资料科学的发展对寡核苷酸合成产业产生直接影响。分析大型基因组数据集的能力不断增强也对市场产生了积极影响。因此,计算能力的提高正在推动对新型寡核苷酸合成的需求增加。此外,寡核苷酸,特别是反义寡核苷酸,已被证明是表观遗传学研究和治疗的有效工具,有助于调节基因表达,从而创造了积极的市场前景。
医疗保健和製药业的需求不断增长
全球对个人化医疗和治疗的需求正在迅速增长,导致寡核苷酸合成市场空前扩张。这些合成的序列是开发针对各种遗传性疾病和疾病(包括癌症)的标靶疗法的不可或缺的组成部分。同时,反义寡核苷酸、适体、siRNA 和免疫刺激寡核苷酸等治疗性寡核苷酸的进步,透过特异性抑製或改变基因表达,正在彻底改变疾病治疗。此外,客製化寡核苷酸的合成是疫苗生产的基础,包括基于 mRNA 的 COVID-19 疫苗,该疫苗已被证明有效且现已广泛使用。随着製药公司和研究人员不断发现寡核苷酸在治疗和预防疾病方面的新应用,寡核苷酸合成的需求即将上升。
技术进步与创新
寡核苷酸合成技术的稳定发展和完善正在推动市场成长。此外,合成製程的创新,包括高通量和自动化合成系统,提高了寡核苷酸生产的效率、准确性和可扩展性。此外,生物资讯学和合成生物学的发展,包括DNA定序和基因编辑(例如CRISPR-Cas9),在很大程度上依赖准确合成寡核苷酸的能力。这些进步允许创建具有更大复杂性和多样性的客製化序列,并促进合成生物学中的快速原型测试,从而促进更有效的研究和开发。这些不断的技术进步和发展也在为市场做出贡献。
不断加强的合作和伙伴关係
製药公司、生技公司和研究机构之间的合作和伙伴关係已成为推动遗传疾病寡核苷酸疗法的开发和商业化的重要驱动力。这些合作汇集了不同的专业知识、资源和资金,创造了一个协同环境,加速将科学发现转化为实际有效的治疗方法。製药公司在药物开发、临床试验和监管流程方面拥有丰富的经验,为此合作贡献了重要的专业知识。他们拥有必要的基础设施、知识和资源来应对药物开发的复杂局面,并确保寡核苷酸疗法符合安全性和有效性的监管标准。他们的参与有助于利用现有网路、製造能力和分销管道简化商业化之路。
IMARC Group提供了全球寡核苷酸合成市场报告各细分市场主要趋势的分析,以及 2023-2028 年全球、区域和国家层面的预测。我们的报告根据产品、应用和最终用途对市场进行了分类。
合成寡核苷酸产品
试剂
装置
服务
合成寡核苷酸产品主导市场
该报告根据产品提供了详细的市场细分和分析。这包括合成的寡核苷酸产品、试剂、设备和服务。根据该报告,合成寡核苷酸产品代表了最大的部分。
製药和生物技术公司对药物发现和开发,特别是个人化医疗和标靶治疗的需求不断增长,推动了寡核苷酸合成产业中合成寡核苷酸产品的市场。同时,在次世代定序 (NGS) 和 CRISPR 基因编辑等技术的重大进步的推动下,基因组学和分子研究的兴起,提高了合成寡核苷酸的需求。此外,寡核苷酸诊断应用的成长,例如遗传性疾病和传染病的 PCR 和微阵列检测,正在推动市场向前发展。表观遗传学领域的不断扩大也是一个关键驱动因素,寡核苷酸在基因表现研究中发挥着至关重要的作用。此外,遗传性疾病的日益普及以及由此产生的对涉及寡核苷酸的新型治疗策略的需求进一步加速了合成寡核苷酸产品的市场成长。
PCR引子
PCR 检测与试剂盒
定序
DNA微阵列
萤光原位杂交 (FISH)
反义寡核苷酸
其他的
PCR引子占据市场主导地位
报告还提供了基于应用程式的详细市场细分和分析。这包括 PCR 引子、PCR 检测和组合、定序、DNA 微阵列、萤光原位杂交 (FISH)、反义寡核苷酸等。根据报告,PCR 引子代表了最大的片段。
持续的全球健康危机推动了寡核苷酸合成产业对 PCR 引子的需求,需要进行广泛的病毒检测,其中 PCR 是主要方法。此外,PCR 在医学诊断、法医学以及检测基因突变和传染病的研究中的应用日益增多,也推动了对引子的需求。在基因组学和分子生物学领域,PCR 被认为是 DNA 定序、克隆和基因操作的重要工具,这种广泛的用途进一步推动了对 PCR 引子合成的需求。除此之外,即时PCR和数位PCR等PCR技术的进步也在刺激需求方面发挥作用。此外,医疗保健和生命科学研究领域的资金不断增加,导致 PCR 的使用扩大,从而推动了整个产业对 PCR 引子的需求。
製药和生物技术公司
医院和诊断实验室
学术研究机构
学术研究机构主导市场
该报告根据产品提供了详细的市场细分和分析。这包括製药和生物技术公司、医院和诊断实验室以及学术研究机构。报告称,学术研究机构占比最大。
学术研究机构对寡核苷酸合成的需求是由基因组学和分子生物学研究的兴起所推动的,特别是与基因表现、遗传性疾病和新型治疗策略的开发相关的研究。此外,依赖合成寡核苷酸的下一代定序 (NGS) 和 CRISPR 基因编辑等技术的进步正在刺激需求。此外,涉及生物资讯学和资料科学的跨学科研究的不断增长趋势,需要使用寡核苷酸进行资料验证,进一步推动了这一需求。政府和机构对基因组学和生物技术研究的资助是另一个主要驱动力,使学术机构能够投资于各种计画的寡核苷酸合成。学术研究机构专注于基础研究和发现,往往拥有前沿知识和创新理念。透过与业界合作,他们可以将科学发现转化为实际应用和商业产品。
北美洲
美国
加拿大
亚太
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
北美表现出明显的主导地位,占据最大的寡核苷酸合成市场份额
该报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。
北美寡核苷酸合成市场由强劲的製药和生物技术产业推动,专注于药物发现和开发。该地区对个人化医疗和标靶治疗的重视进一步推动了这一需求。此外,北美复杂的医疗保健系统和先进的诊断能力增加了诊断分析中对寡核苷酸的需求。该地区还拥有许多顶级学术和研究机构,进行广泛的基因组学和分子生物学研究,这需要寡核苷酸合成。此外,政府和私营部门对医疗保健和生命科学研究,特别是基因组学和个人化医疗的大力投资,推动了北美工业的成长。此外,北美基于寡核苷酸的疗法的输送系统和配方的进步表明该地区致力于突破该领域的创新界限。这些发展不仅有助于市场的成长,而且有可能彻底改变各种疾病的治疗,包括遗传性疾病、癌症和罕见疾病。
由于开发新生产设施、升级现有设施以及实施更有效率的生产流程的投资不断增加,全球寡核苷酸合成市场正在经历显着成长。因此,该公司正在大力投资研发以创新其产品,包括开发新的合成技术、提高合成的规模和准确性,以及创造新型寡核苷酸产品以支持诊断、治疗和研究中的各种应用。同时,公司正进入策略合作、伙伴关係和收购,共同开发基于寡核苷酸的药物、共享技术和专业知识或拓展新市场。此外,反义寡核苷酸、siRNA 和 miRNA 等疗法的引入为治疗包括遗传性疾病和癌症在内的多种疾病提供了新途径,对市场产生了积极影响。此外,主要参与者正在提供寡核苷酸的客製化合成服务。这使得研究人员和开发人员能够根据自己的需求订购特定的寡核苷酸序列,这在基因组学、分子生物学和个人化医疗等领域尤其重要。
安捷伦科技公司
比奥莱吉奥有限公司
生物合成公司
欧陆基因公司
金斯瑞
地平线探索有限公司
Integrated DNA Technologies Inc(丹纳赫公司)
钟化 Eurogentec SA(钟化株式会社)
LGC有限公司
Nitto Denko Avecia Inc(日东电工株式会社)
赛默飞世尔科技公司
2023年5月,金斯瑞扩大了其位于中国江苏镇江的主要製造工厂的规模,用于生产寡核苷酸和胜肽。此次扩张建立在金斯瑞 20 年来为世界各地的科学家提供一流寡核苷酸和胜肽的历史基础上。
2023 年 1 月,安捷伦科技公司宣布增加治疗性核酸(也称为寡核苷酸)的产量。该倡议是该行业为应对快速发展而进行的一系列投资中的最新倡议。安捷伦位于科罗拉多州弗雷德里克的工厂宣布于 2020 年安装一条生产线,预计今年稍后开始运营,该项目将增加两条寡核苷酸生产线。
2022 年 2 月,Kaneka Eurogentec SA(钟化株式会社)表示,为美国客户批量生产的 25 g mRNA 已在其 mRNA 合成工厂成功生产。在其位于比利时的现有工厂中,Eurogentec 的 GMP mRNA 生产服务提供 GMP 材料的体外转录 (IVT)、纯化、品质控制和批量放行,最大可达 25 g 规模。
The global oligonucleotide synthesis market size reached US$ 2.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2028, exhibiting a growth rate (CAGR) of 12.6% during 2022-2028. The growing prevalence of genetic diseases among the masses, the development of novel therapeutic strategies, and the widespread adoption of therapies using small interfering RNAs (siRNAs), and antisense oligonucleotides are some of the major factors propelling the market.
Oligonucleotide synthesis refers to the process of constructing short DNA or RNA molecules, called oligonucleotides, in a predetermined sequence. These can range from just a few bases to around 200 nucleotides in length. The process is accomplished chemically in a controlled laboratory environment, typically using solid phase phosphoramidite chemistry. In this method, nucleotides are sequentially added to a growing chain, each addition involving a series of chemical reactions. This technology enables scientists to generate custom-made oligonucleotides for various applications including gene synthesis, polymerase chain reaction (PCR), gene editing tools, such as CRISPR-Cas9, and molecular diagnostic tests. Advances in oligonucleotide synthesis have dramatically accelerated research in genomics and molecular biology, underpinning many breakthroughs in medical and biological research.
The rising prevalence of genetic diseases among the masses majorly drives the global market. This necessitates the development of novel therapeutic strategies, where oligonucleotide-based therapies play a significant role. For instance, therapies using small interfering RNAs (siRNAs) and antisense oligonucleotides are being investigated and utilized in the treatment of genetic disorders, such as Duchenne muscular dystrophy and spinal muscular atrophy. As such, the growing prevalence of genetic diseases drives the demand on the global level. Along with this, the growth of bioinformatics and data science has a direct impact on the oligonucleotide synthesis industry. The escalating capacity to analyze large genomic datasets is also positively influencing the market. Therefore, the rising computational capability is driving an increased demand for the synthesis of novel oligonucleotides. Furthermore, oligonucleotides particularly antisense oligonucleotides, have been shown to be effective tools in epigenetic research and therapy, helping to modulate gene expression, which is creating a positive market outlook.
Rising Demand in the Healthcare and Pharmaceutical Industries
The global demand for personalized medicine and therapeutics is rapidly increasing, leading to an unprecedented expansion in the oligonucleotide synthesis market. These synthesized sequences are integral components in developing targeted therapies for various genetic disorders and diseases, including cancer. Along with this, the advancement of therapeutic oligonucleotides, such as antisense oligonucleotides, aptamers, siRNAs, and immunostimulatory oligonucleotides, is revolutionizing disease treatment by specifically inhibiting or altering gene expression. Furthermore, the synthesis of custom oligonucleotides is fundamental to the production of vaccines, including mRNA-based COVID-19 vaccines, which have proven effective and are now widely used. As pharmaceutical companies and researchers continue to discover novel applications for oligonucleotides in the treatment and prevention of diseases, the demand for oligonucleotide synthesis is poised to rise.
Technological Advancements and Innovation
The steady development and refinement of oligonucleotide synthesis technologies are driving market growth. In addition, innovations in the synthesis process, including high-throughput and automated synthesis systems, have increased the efficiency, accuracy, and scalability of oligonucleotide production. Moreover, developments in bioinformatics and synthetic biology, including DNA sequencing and gene editing (e.g., CRISPR-Cas9), heavily rely on the ability to synthesize oligonucleotides accurately. These advancements allow for the creation of custom sequences with greater complexity and diversity and facilitate rapid prototype testing in synthetic biology, thereby fostering more efficient research and development. These continuous technological advancements and developments are also contributing to the market.
Growing Collaborations and Partnerships
Collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions have become essential drivers in advancing the development and commercialization of oligonucleotide therapies for genetic diseases. These collaborations bring together diverse expertise, resources, and funding, creating a synergistic environment that accelerates the translation of scientific discoveries into practical and effective treatments. Pharmaceutical companies, with their experience in drug development, clinical trials, and regulatory processes, contribute vital expertise to the collaboration. They have the infrastructure, knowledge, and resources necessary to navigate the complex landscape of drug development and ensure that oligonucleotide therapies meet regulatory standards for safety and efficacy. Their involvement helps streamline the path to commercialization by leveraging existing networks, manufacturing capabilities, and distribution channels.
IMARC Group provides an analysis of the key trends in each segment of the global oligonucleotide synthesis market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, application and end use.
Synthesized Oligonucleotide Products
Reagents
Equipment
Services
Synthesized oligonucleotide products dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes synthesized oligonucleotide products, reagents, equipment, and services. According to the report, synthesized oligonucleotide products represented the largest segment.
The market for synthesized oligonucleotide products in the oligonucleotide synthesis industry is being driven by the ever-increasing demand from pharmaceutical and biotechnological companies for drug discovery and development, especially for personalized medicine and targeted therapeutics. Along with this, the rise in genomics and molecular research, fueled by significant advancements in technologies such as Next Generation Sequencing (NGS) and CRISPR gene-editing, is enhancing the requirement for synthesized oligonucleotides. Additionally, the growth in diagnostic applications of oligonucleotides, such as in PCR and microarray assays for genetic and infectious diseases, is propelling the market forward. The expanding field of epigenetics also represents a key driver, with oligonucleotides playing a crucial role in gene expression studies. Moreover, the increasing prevalence of genetic disorders and the resultant demand for novel therapeutic strategies involving oligonucleotides further accelerates the market growth for synthesized oligonucleotide products.
PCR Primers
PCR Assays and Panels
Sequencing
DNA Microarrays
Fluorescence In-Situ Hybridization (FISH)
Antisense Oligonucleotides
Others
PCR primers dominate the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes PCR primers, PCR assays and panels, sequencing, DNA microarrays, Fluorescence In-Situ Hybridization (FISH), antisense oligonucleotides, and others. According to the report, the PCR primers represented the largest segment.
The demand for PCR primers in the oligonucleotide synthesis industry is driven by the ongoing global health crisis necessitating extensive viral testing, in which PCR is a primary method. Furthermore, the increasing application of PCR in medical diagnostics, forensics, and research to detect genetic mutations and infectious diseases fuels the demand for primers. In the field of genomics and molecular biology, PCR is considered a crucial tool for DNA sequencing, cloning, and genetic manipulation, and this broad utilization further drives the need for PCR primer synthesis. Apart from this, technological advancements in PCR techniques, such as real-time PCR and digital PCR, are also playing a role in boosting demand. Moreoevr, the growing funding for research in healthcare and life sciences has resulted in expanded use of PCR, thus driving the demand for PCR primers in the overall industry.
Pharmaceutical and Biotechnology Companies
Hospital and Diagnostic Laboratories
Academic Research Institutes
Academic research institutes dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, and academic research institutes. According to the report, academic research institutes represented the largest segment.
The demand for oligonucleotide synthesis in academic research institutes is driven by a rise in genomics and molecular biology research, particularly studies related to gene expression, genetic disorders, and the development of novel therapeutic strategies. Additionally, advancements in technologies such as Next-Generation Sequencing (NGS) and CRISPR gene-editing, which rely on synthesized oligonucleotides, are stimulating demand. In addition, the rising trend of interdisciplinary studies involving bioinformatics and data science, which necessitate the use of oligonucleotides for data validation, further drives the need. Governmental and institutional funding for genomics and biotechnology research is another major driver, enabling academic institutes to invest in oligonucleotide synthesis for various projects. Academic research institutes, with their focus on fundamental research and discovery, often possess cutting-edge knowledge and innovative ideas. By partnering with industry, they can translate their scientific findings into practical applications and commercial products.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest oligonucleotide synthesis market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The North American market for oligonucleotide synthesis is propelled by a robust pharmaceutical and biotech industry, with a strong focus on drug discovery and development. The region's emphasis on personalized medicine and targeted therapies further propels this need. Additionally, North America's sophisticated healthcare system with advanced diagnostic capabilities increases the demand for oligonucleotides in diagnostic assays. The region also hosts numerous top-tier academic and research institutes conducting extensive genomics and molecular biology research, which necessitates oligonucleotide synthesis. Moreover, strong governmental and private sector investment in healthcare and life sciences research, particularly in genomics and personalized medicine, fuels the growth of industry in North America. Moreover, the advancements in delivery systems and formulations for oligonucleotide-based therapeutics in North America demonstrate the region's commitment to pushing the boundaries of innovation in this field. These developments not only contribute to the growth of the market but also have the potential to revolutionize the treatment of various diseases, including genetic disorders, cancers, and rare diseases.
The global oligonucleotide synthesis market is experiencing significant growth due to the escalating investments in the development of new production facilities, upgrading existing ones, and implementing more efficient production processes. Therefore, Companies are heavily investing in research and development to innovate their offerings, including developing new synthesis techniques, improving the scale and accuracy of synthesis, and creating new types of oligonucleotide products to support various applications in diagnostics, therapeutics, and research. Along with this, companies are entering into strategic collaborations, partnerships, and acquisitions to co-develop oligonucleotide-based drugs, share technology and expertise, or expand into new markets. In addition, the introduction of therapeutics, such as antisense oligonucleotides, siRNAs, and miRNAs, offer new avenues for treating a wide range of diseases, including genetic disorders and cancers is positively influencing the market. Furthermore, key players are offering services for the custom synthesis of oligonucleotides. This allows researchers and developers to order specific oligonucleotide sequences tailored to their needs, which is particularly important in fields like genomics, molecular biology, and personalized medicine.
Agilent Technologies Inc.
Biolegio B.V.
Bio-Synthesis Inc
Eurofins Genomics
GenScript
Horizon Discovery Ltd
Integrated DNA Technologies Inc (Danaher Corporation)
Kaneka Eurogentec S.A. (Kaneka Corporation)
LGC Limited
Nitto Denko Avecia Inc (Nitto Denko Corporation)
Thermo Fisher Scientific Inc.
In May 2023, GenScript increased the size of its principal manufacturing plant in Zhenjiang, Jiangsu, China for the manufacture of oligonucleotides and peptides. The expansion builds on GenScript's history of providing top-notch oligo and peptides to scientists all across the world for 20 years.
In January 2023, Agilent Technologies Inc. announced to increase its production of therapeutic nucleic acids, also known as oligonucleotides. The initiative is the most recent in a series of investments done by the sector in response to rapid development. At Agilent's plant in Frederick, Colorado, where the installation of a line announced in 2020 is slated to commence operating later this year, the project will add two oligonucleotide production lines.
In February 2022, Kaneka Eurogentec S.A. (Kaneka Corporation) stated that a 25 g batch of mRNA for a US customer had been successfully manufactured at its mRNA synthesis facility. In its present facility in Belgium, Eurogentec's GMP mRNA production service provides in vitro transcription (IVT), purification, quality control, and batch release of GMP material up to 25 g scale.